VEGF in Iris Tissue in Primary Congenital Glaucoma

Iris Clinical Trial

Official title:

Estimation of Vascular Endothelial Growth Factor (VEGF) in Iris Tissue in Primary Congenital Glaucoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05484050
• Other study ID #: 2323300
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 2022
• Est. completion date: June 2023

Study information

• Verified date: July 2022
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Estimation of vascular endothelial growth factor (VEGF) in iris tissue specimen in primary congenital glaucoma through Immunohistochemistry.

Description:

Combined trabeculotomy with mitomycin C will done in infants with primary congenital glaucoma with histopathological examination of the the peripheral iris tissue specimen and vascular endothelial growth factor (VEGF) estimation in iris tissue specimen through Immunohistochemistry.

Estimation of vascular endothelial growth factor (VEGF) in iris tissue specimen taking from ocular trauma or congenital cataract used as control.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: June 2023
• Est. primary completion date: March 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Day to 1 Year

Eligibility

Inclusion Criteria:

• primary congenital glaucoma

Exclusion Criteria:

• Infants with history of previous surgery.

• Secondary glaucoma.

• Glaucoma associated with other congenital anomalies.

Related Conditions & MeSH terms

• Glaucoma
• Iris

Intervention

Other:
• Immunohistochemistry analysis
Estimation of VEGF through Immunohistochemistry

Locations

Country	Name	City	State
Egypt	Hassan Lotfy	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Hassan Lotfy Fahmy

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	VEGF	Estimation of VEGF grade in iris tissue through Immunohistochemistry, The grades is arranged from 0 to 5, with 0 being the lowest level and 5 being the highest level	6 month